All times are listed in CET (Central European Time)
Found 1 Presentation For Request "131P"
131P - Predictive factors of response to PD-(L)1 inhibitors in patients with advanced non-small cell lung (NSCLC) and high PD-L1 expression
- A. Barba Joaquín (Barcelona, Spain)
- A. Barba Joaquín (Barcelona, Spain)
- A. Piedra (Barcelona, Spain)
- J. Mosquera (a Coruña, Spain)
- M. Riudavets Melià (Villejuif, France)
- M. Gomez-Randulfe (a Coruña, Spain)
- M. Garcia Campelo (A Coruña, Spain)
- I. Sullivan (Barcelona, Spain)
- J. Serra (Barcelona, Spain)
- M. Aguado (Barcelona, Spain)
- M. Majem Tarruella (Barcelona, Spain)
Abstract
Background
Tumor PD-L1 expression is the only biomarker predictive of responsiveness in advanced NSCLC treated with PD-(L)1 inhibitors. Analysis of PD-L1 expression by IHC has been validated in histological samples. Smoking and overweight have been described as predictive factors of better outcome, whereas bone metastases,antibiotic, corticosteroids and proton pump inhibitors as predictive factors of poor outcome. The aim of our study was to analyze potential predictive factors of response to PD-(L)1 inhibitors in patients (pts) with advanced NSCLC and high PD-L1 expression.
Methods
The study was carried out in pts with advanced NSCLC and high PD-L1 expression treated with PD-(L)1 inhibitors. Clinical and histological variables of interest were registered. Kaplan-Meier estimations were used to calculate survival, and log-rank test to make comparisons. The impact of variables on survival was assessed through univariate and multivariate analysis. We present preliminary results of the analysis.
Results
86 pts were included in the analysis. Mean age was 66 y [36–84], 21 (24.4%) were females, 73.3% former smokers and 22.1% current smokers, 38,4% presented normal BMI, 79% had non-squamous NSCLC, 85% received PD-(L)1 inhibitors in first line and 12% pts had cytological sample for PD-L1 determination. 72 (84%) pts received monotherapy with PD-(L)1 inhibitor, 4 (5%) pts CT plus PD-(L)1 inhibitor and 10 (11.6%) pts received PD-(L)1 inhibitors with other immunotherapy. The mean OS and PFS were 14.1 and 9.6 months, respectively. ORR and DCR in overall patients were 57% and 72.7%, respectively and ORR and DCR in pts treated in first line were 57.6% and 73.4%, respectively. Better results were detected in overweight and in smoker pts despite not being estatistically significant. A trend to worse OS was observed in pts with bone metastasis. No differences in OS were observed according to the type of tumor sample (cytological and histological samples).
Conclusions
Preliminary results showed that smoking and overweight could be potential predictive factors of better outcome withe bone metastasis potential predictive factors of poor outcome, and no differences in survival were observed according to the type of tumor sample.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Barba Joaquín: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Travel/Accommodation/Expenses: Merk; Speaker Bureau/Expert testimony: Bristol; Speaker Bureau/Expert testimony: Angelini. M. Riudavets: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Merk. M.R. Garcia Campelo: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Merk; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Speaker Bureau/Expert testimony: Boehringer; Speaker Bureau/Expert testimony: AstraZeneca. I.G. Sullivan: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Merk; Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: AstraZeneca. M. Majem Tarruella: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BMS; Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: Boehringer; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: Pfizer. All other authors have declared no conflicts of interest.